Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Veradigm, a biotech company, is undergoing leadership changes with the departure of its CEO. The reason for the CEO's departure is expected to impact the sales process and attract attention during due diligence by prospective buyers. The company is exploring a potential sale.
BioCentury's latest roundup of management moves: Neurocrine’s Gorman to retire as CEO. Plus: Eisner becomes CMO of Vir and updates from Entact, Gates Medical Research Institute, Compass, Armonica and Omega $NBIX $VIR $CMPX $OMGA https://t.co/t1BhqL0lDl
American Vanguard Announces Retirement of COO https://t.co/rX6e9nJmAh https://t.co/xseFQFr2du
Neurocrine, a regular name on Wall Street’s M&A lists, elevates BD chief to succeed founder and CEO https://t.co/JuEhUn8GTs
